
 <p style="font-size: 1.2em; margin: 0;">INFORMATION DISCLOSURE CITATION</p> <p style="margin: 0;">PTO-1449</p>				ATTY. DOCKET NO. A-68668/RFT/TAL		SERIAL NO. 09/454,481		
				APPLICANT ALLISON et al.				
				FILING DATE December 3, 1999		GROUP 1642		
U.S. PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
SR	1	5,434,131	7/1995	Linsley et al.	514	2	/	
SR	2	5,565,763	9/1996	Ochoa et al.	435	7.23		
FOREIGN PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No	
SR	3	97/20574	12/1997	PCT	/	/	/	/
SR	4	98/42752	10/1998	PCT				
SR	5	90/05541	5/1990	PCT				
SR	6	0 613 944	9/1994	EP				
SR	7	0 682 039	11/1995	EP				
SR	8	95/34320	12/1995	PCT				
SR	9	95/01994	1/1995	PCT				
SR	10	96/14865	5/1996	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
SR	11	Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," Proc. Natl. Acad. Sci. USA, 95:10067-10071 (1998).						
SR	12	Thompson et al., "The Emerging Role of CTLA-4 as an Immune Attenuator," Immunology, 7:445-450 (1997).						
SR	13	Cepero et al., "Potent inhibition of CTLA-4 expression by an Anti-CTLA-4 ribozyme," Biochemical and Biophysical Research Communications, 247:838-843 (1998).						
SR	14	Van Elsas et al., "Blockade of CTLA-4 combined with a GM-CSF vaccine cures mice from the highly tumorigenic, poorly immunogenic melanoma B16-BL6, and induces depigmentation," The FASEB Journal, 12(5):A908, abstract #5258 (1998).						
EXAMINER <i>J. Raulings</i>				DATE CONSIDERED <i>5/16/01</i>				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
8085 1449A.FRM (8/95)

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO.
A-68668/RFT/TALSERIAL NO.
09/454,481APPLICANT
ALLISON et al.FILING DATE
December 3, 1999GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
SR	15	93/00431	1/1993	PCT			
SR	16	95/33770	12/1995	PCT			
SR	17	95/24217	9/1995	PCT			
SR	18	95/03408	2/1995	PCT			
SR	19	95/05464	2/1995	PCT			
SR	20	95/23859	9/1995	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SR	21	Poplonski et al., "Tolerance is overcome in beef insulin-transgenic mice by activation of low-affinity autoreactive T cells," Eur. J. Immunol. 26:601-606 (1996).
SR	22	Morgan et al., "Activation of low avidity CTL for self-epitope results in tumor rejection by not autoimmunity," J. Immunol. 160:643-651 (1998).
SR	23	Overwijk et al., "gp100/pmel 17 is a murine tumor rejection antigen: induction of "Self'-reactive tumoricidal T cells using high-affinity, altered peptide ligand," J. Exp. Med. 188:277-286 (1998).
SR	24	Ehl et al., "Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology," J. Exp. Med. 187:763-774 (1998).
SR	25	Owerwijk et al., "Vaccination with a recombinant vaccinia virus encoding a "self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes," Proc. Natl. Acad. Sci. USA. 96:2982-2987 (1999).

EXAMINER

J. Rauling

DATE CONSIDERED

5/16/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8085 1449A.FRM (8/95)